Regeneron Pharmaceuticals | REGN - Operating Expenses



Regeneron Pharmaceuticals reported $2.6B in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Agios Pharmaceuticals USD 139.51M 24.16M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
Amgen USD 6.52B 337M Jun/2025
Astellas Pharma JPY 413.25B 17.48B Jun/2025
AstraZeneca USD 10.95B 1.04B Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
GlaxoSmithKline GBP 5.96B 663M Jun/2025
Incyte USD 904.7M 56.97M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
J&J USD 16.8B 8.54B Jun/2025
Kyowa Hakko Kirin JPY 113.11B 15.82B Jun/2025
Merck USD 9.44B 217M Jun/2025
Moderna USD 1.04B 113M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Novartis USD 9.37B 782M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024
Sanofi EUR 8.8B 2.03B Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
Teva Pharmaceutical Industries USD 3.28B 95M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
United Therapeutics USD 521.7M 110.1M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025